ReviewCancer control : journal of the Moffitt Cancer Center
Unveiling the Paradoxical Nature of Autophagy in Cancer Cell Fate.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Reprogramming Autophagy to Strengthen Antitumour Immunity: Advances in Immunotherapeutic Strategies.Immunology · 2026Review
- Autophagy Modulation in Cancer Therapy: Navigating the Dual Roles to Overcome Chemoresistance.Health science reports · 2026Article
- Enhanced anti-tumor effects of Imatinib and immune checkpoint inhibitors on gastrointestinal stromal tumor cells (GISTs): insights from monoculture and 3D co-culture models.Medical oncology (Northwood, London, England) · 2026Article
- Autophagy-Circulating Tumor DNA Axis in Molecular Cancer Research: Emerging Mechanisms, Therapeutic Targeting, and Translational Opportunities.International journal of molecular sciences · 2026Review
- Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition.Exploration of targeted anti-tumor therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy is an ancient conserved and catabolic process required to maintain cellular homeostasis through sequestration and lysosomal degradation of cytosolic dysfunctional contents. The bulk degradation of cytosolic material through autophagy provides the necessary nutrients that cells utilize under starvation. Autophagy can play a mixed role in both the growth and survival of cancer cells. As a damaged cellular content-clearing mechanism, autophagy is involved in the early stage of tumor regression. Subsequently, in a mature tumor cell microenvironment, autophagy protects tumor cells from cellular stress, immune evasion, and therapeutic resistance. Therapeutic resistance mediated by autophagic regulators can make anticancer therapy less effective. This review discusses the molecular mechanism of mammalian autophagy, evaluates the dynamic role of autophagy in cancer, highlights autophagy-mediated therapeutic resistance, and suggests the use of biomarkers. In cancer therapy, the addition of biomarkers can provide specific identification, and the conjugation of biomarkers with chemo-drugs can reduce the side effects and ensure normal cell integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.